Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Delivery Hero cuts FY profit outlook

(Sharecast News) - German takeaway food delivery firm Delivery Hero has cut its full-year profit outlook citing foreign exchange headwinds. The company now expects FY25 adjusted earnings before interest, tax, depreciation and amortisation of between €900m and €940m, down from previous guidance of €975m to €1.03bn. It pointed to around €110m of foreign exchange headwinds.

It also said it now expects free cash flow of more than €120m, down from previous guidance of more than €200m, as a result of about €80m foreign exchange headwinds.

Had it not been for these headwinds, Delivery Hero said it would have been on track to meet its previous guidance on adjusted EBITDA and free cash flow.

The downgraded guidance - issued late on Wednesday - was offset by solid second-quarter numbers on Thursday, which showed that total like-for-like revenue grew 27% to €3.7bn, while group gross merchandise value was 11% higher on a LFL basis at €12.2bn.

First-half adjusted EBITDA jumped 71% from the same period a year earlier to €411m, with the margin expanding by 70 basis points to 1.7% of GMV.

Chief executive and co-founder Niklas Östberg said: "We built on our strong start to the year, delivering accelerated growth and expanded profitability in the second quarter.

"We achieved new daily order records and I am particularly encouraged by our performance in Asia, where we have seen a clear improvement in both customer input metrics and GMV growth."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.